Literature DB >> 22170541

Hepatitis C virus genotyping in Greece: unexpected high prevalence of genotype 5a in a Greek island.

Stylianos Karatapanis1, Panagiota Tsoplou, Vasilios Papastergiou, Aggeliki Vasiageorgi, Maria Stampori, Ioannis Saitis, Eustathios Tsitsopoulos, Phillipos Lisgos, Lamprini Skorda, Ioannis Ketikoglou, Ioannis Goulis.   

Abstract

Hepatitis C virus (HCV) genotype 5 (G5) is a rare genotype reported mainly in South Africa. However, increasing data suggest the sporadic presence of this genotype in different European countries. To assess the epidemiology of HCV-G5 in Greece, genotyping was performed in 973 consecutive patients infected with HCV, referred to 7 hepatology centers throughout Greece, from January 2005 to December 2009. Genotype 5a (19 patients, 1.9%) was the fifth most prevalent genotype after genotype 1 (408 patients, 41.9%), genotype 3 (318 patients, 32.7%), genotype 4 (158 patients, 16.2%), and genotype 2 (70 patients, 7.2%). The majority of patients infected with G5 (16/19,84.2%) were referred to the General Hospital of Rhodes, an island in south-east Greece. The HCV genotype distribution in that particular island, indicates a particularly high G5 prevalence of 12.8%, after genotype 1 (40%), genotype 3 (28%), and genotype 4 (15%). Among the patients from Rhodes infected with G5 (n = 16), 13 (81.2%) were females. The mean age was 62.3 ± 6.5 years, significantly older than the patients infected with other HCV genotypes (mean age 40.6 ± 7.2, P < 0.0001). Nine out of the 16 cases (56.2%) presented features of high pre-treatment viral loads. Advanced liver fibrosis (Metavir F3-F4) was found in four out of five performed liver biopsies. Ten patients received treatment with pegylated interferon plus ribavirin and a sustained viral response were achieved in six cases. The source of infection is unknown but parenteral iatrogenic routes of transmission seem to have contributed significantly to the spread of genotype 5a in this region.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22170541     DOI: 10.1002/jmv.22249

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  8 in total

Review 1.  Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes.

Authors:  Simona Ruta; Costin Cernescu
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

Review 2.  Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6.

Authors:  Vasilios Papastergiou; Stylianos Karatapanis
Journal:  World J Clin Cases       Date:  2015-03-16       Impact factor: 1.337

3.  Effects of chronic hepatitis C genotype 1 and 4 on serum activins and follistatin in treatment naïve patients and their correlations with interleukin-6, tumour necrosis factor-α, viral load and liver damage.

Authors:  Bassem Refaat; Ahmed Mohammed Ashshi; Adel Galal El-Shemi; Adnan AlZanbagi
Journal:  Clin Exp Med       Date:  2014-06-13       Impact factor: 3.984

Review 4.  Sustained virologic response to standard interferon or pegylated interferon and ribavirin in patients with hepatitis C virus genotype 5: systematic review and meta-analysis of ten studies and 423 patients.

Authors:  Pardha Devaki; David Jencks; Brittany E Yee; Mindie H Nguyen
Journal:  Hepatol Int       Date:  2015-05-28       Impact factor: 6.047

5.  Eleven-year distribution pattern of hepatitis C virus in southern Italy.

Authors:  Nadia Marascio; Giovanni Matera; Angela Quirino; Aida Giancotti; Giorgio S Barreca; Angelo G Lamberti; Benedetto Caroleo; Maria Carla Liberto; Alfredo Focà
Journal:  J Pathog       Date:  2012-08-09

Review 6.  Activins and Follistatin in Chronic Hepatitis C and Its Treatment with Pegylated-Interferon-α Based Therapy.

Authors:  Bassem Refaat; Ahmed Mohamed Ashshi; Adel Galal El-Shemi; Esam Azhar
Journal:  Mediators Inflamm       Date:  2015-04-19       Impact factor: 4.711

Review 7.  Epidemiology of hepatitis C in Greece.

Authors:  Christos Triantos; Christos Konstantakis; Paraskeui Tselekouni; Maria Kalafateli; Ioanna Aggeletopoulou; Spilios Manolakopoulos
Journal:  World J Gastroenterol       Date:  2016-09-28       Impact factor: 5.742

Review 8.  Aspects on the history of transmission and favor of distribution of viruses by iatrogenic action: perhaps an example of a paradigm of the worldwide spread of HIV.

Authors:  Lutz G Gürtler; Josef Eberle
Journal:  Med Microbiol Immunol       Date:  2017-04-22       Impact factor: 3.402

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.